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Background: 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is a widely used recreational drug known to
impair cognitive functions on the long-run. Both hippocampal and frontal cortical regions have well established
roles in behavior, memory formation and other cognitive tasks and damage of these regions is associated with
altered behavior and cognitive functions, impairments frequently described in heavy MDMA users. The aim of this
study was to examine the hippocampus, frontal cortex and dorsal raphe of Dark Agouti rats with gene expression
arrays (Illumina RatRef bead arrays) looking for possible mechanisms and new candidates contributing to the effects
of a single dose of MDMA (15 mg/kg) 3 weeks earlier.
Results: The number of differentially expressed genes in the hippocampus, frontal cortex and the dorsal raphe
were 481, 155, and 15, respectively. Gene set enrichment analysis of the microarray data revealed reduced expression of
‘memory’ and ‘cognition’, ‘dendrite development’ and ‘regulation of synaptic plasticity’ gene sets in the hippocampus,
parallel to the upregulation of the CB1 cannabinoid- and Epha4, Epha5, Epha6 ephrin receptors. Downregulated gene
sets in the frontal cortex were related to protein synthesis, chromatin organization, transmembrane transport processes,
while ‘dendrite development’, ‘regulation of synaptic plasticity’ and ‘positive regulation of synapse assembly’ gene sets
were upregulated. Changes in the dorsal raphe region were mild and in most cases not significant.
Conclusion: The present data raise the possibility of new synapse formation/synaptic reorganization in the frontal cortex
three weeks after a single neurotoxic dose of MDMA. In contrast, a prolonged depression of new neurite formation in
the hippocampus is suggested by the data, which underlines the particular vulnerability of this brain region after the
drug treatment. Finally, our results also suggest the substantial contribution of CB1 receptor and endocannabinoid
mediated pathways in the hippocampal impairments. Taken together the present study provides evidence for the
participation of new molecular candidates in the long-term effects of MDMA.
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Ecstasy (3,4-methylenedioxymethamphetamine, MDMA)
is an amphetamine derivative widely abused for its eu-
phoric and entactogenic effects in developed countries
[1,2]. The acute indirect monoaminergic agonist ef-
fects of MDMA are mainly mediated by an increase
in serotonergic, noradrenergic and dopaminergic neuro-
transmission of the brain by reversing transmembrane
transporter functions, which are normally responsible for
the uptake of neurotransmitters from the synaptic cleft
[1-4]. However, in the long-run, a decrease in seroto-
nergic markers was reported in experimental animals
and also in human users suggesting a long-term se-
lective vulnerability of the serotonergic system [2,5-7].
Functional deficits could also be observed in humans
and in rodents, e.g. impaired decision making, sleep
disturbances, increased anxiety and impulsivity levels,
elevated aggression, learning and memory impairments
and depression [2,6,8-10]. Additionally to the selective
damage observed in serotonergic neurons, MDMA
may also cause more wide-spread neurotoxicity, pos-
sibly by its hyperthermic effect and the production of
toxic metabolites and free radicals or via the disruption
of local cerebral blood flow and glucose utilization,
which might cause alterations in the nutrition-supply
of neurons [5,11-19].
The serotonergic projections in the mammalian brain,
the primary targets of MDMA’s effects in rats, originate
from the raphe nuclei in the brainstem. Dorsal (DR) and
medial raphe nuclei innervate upper brain structures, in-
cluding the frontal cortical regions and the hippocampus
(HC) [20-23]. The frontal cortex (FC) plays major roles
in risk evaluation [24], executive functioning [24,25], and
working memory [26-28], while its malfunctions may be
associated with neuropsychiatric diseases [24,29]. At the
same time, HC has a pivotal role in contextual and hereby
spatial memory formation [23,30] thus all of the latter re-
gions are candidates for long-run functional deficits caused
by MDMA.
Parallel to the neuronal damage, however, neuropro-
tective mechanisms also occur and, later in time, recov-
ery processes also may begin. Heat-shock proteins
(HSPs) can ameliorate the damage caused by cellular
stress of different origin, e.g. hyperthermia, ischemia, or
excessive production of free radicals [31]. Elevated levels
of HSP 27 in the FC and HC 3 days after MDMA treat-
ment was demonstrated by Adori et al. and this elevation
persisted until at least 7 days in the HC but normalized
in the FC by this time [5]. Brain-derived neurotrophic
factor (BDNF), a well-characterized member of neuro-
trophic factors, is involved in several processes maintain-
ing central nervous system (CNS) functions like dendritic
arborization, synaptogenesis and activity-dependent
potentiation (for reviews see [32] and [33]). A studyelucidating MDMA’s effects on BDNF mRNA expression
reported ever increasing elevations in FC up to 7 days
after MDMA administration while in the HC a decrease
was evident [34]. Investigation of MDMA’s long-term ef-
fects revealed that in the parietal cortex BDNF protein
levels peaked at 8 weeks after an initial decline but in the
HC no significant change could be reported [35]. All of
the latter results suggest different recovery capacities of
the HC and FC, but the detailed biochemical mecha-
nisms responsible for these differences remained so far
less investigated at later time points. We speculated
that these consequences might be already visible at 21
days following a single dose of MDMA thus we per-
formed our analysis 3 weeks after drug administration to
investigate both the recovery processes and the down-
stream mediators of damages.
Studies examining transcriptional changes following
MDMA administration are scarce, only few reports eval-
uated alterations in mRNA levels of genes which were
assumed to be related to MDMA effects [6,10,35-41].
Thus, the aim of this study was to address the down-
stream transcriptional consequences of MDMA’s effects
and to find possible new targets of regulatory mecha-
nisms by using large-scale gene expression profiling in
the HC, FC, and DR regions of DA rats 21 days after
a single-dose MDMA administration. Additionally, we
also addressed whether signs of functional recovery on
the molecular level can occur in the FC and HC re-
gions and if so, whether they differ in quality or quan-
tity in these two regions. Furthermore, for comparable
results with our earlier studies, we used the same dos-
age regimen (15 mg/kg) in the Dark Agouti (DA) rat
strain, which represents the human “poor metabolizer”
phenotype [42].
Results
General overview of gene expression alterations
Comparison of the gene expression profiles showed 615
differentially expressed genes in the MDMA treated group
compared to the saline control (minimum probability of
positive log ratio [MinPplr] < 0.001) (Figure 1). In the HC
region 481 genes showed altered expression, 310 and 171
genes were up- or downregulated, respectively. From
155 significant genes in the FC region 89 were up- and
66 downregulated. Only 14 unique genes were altered in
the DR region, 3 showed elevated expression and the
remaining 11 showed a decrease compared to the control
group. All genes emphasized below were selected by indi-
vidual considerations of MDMA’s known effects and
related literature data. For full results see Additional file 1:
Table S1.
The GSEA analysis revealed 18, 55 and 1 differen-
tially regulated gene sets in the HC, FC and DR regions,
respectively.
Hippocampus
Frontal Cortex
Dorsal Raphe
445
119
14
35
1
Figure 1 Venn-diagram representation of significantly altered
mRNAs. Venn-diagrams showing the number of significantly
(minimum probability of positive log ratio (MinPplr) < 0.001) up- or
downregulated genes in the hippocampus (HC), frontal cortex (FC)
and dorsal Raphe (DR) of Dark Agouti (DA) rats 3 weeks after a
single-dose of 3,4-methylenedioxymethamphetamine (MDMA)
(15 mg/kg, intraperitoneally). Altogether 615 genes’ showed altered
expression, 481, 155, 14 genes in the HC, FC, DR regions, respectively.
Among them only 1 genes’ expression altered significantly in all three
regions and 36 genes differed significantly compared to saline controls
in both the FC and HC groups. See text for further details.
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Differentially expressed genes
Changes in major hippocampal neurosignaling pathways
included an elevation in the type 1 cannabinoid re-
ceptor (Cnr1, CB1), glutamatergic AMPA3 (Ampa3)
and GRIN2A receptor mRNA levels (Gria3), parallel with
an increased expression of Epha4 (LOC316539), Epha5
and Epha6 receptors, members of ephrin signaling. Add-
itionally the GABA-A receptor subunit (Gabre) was down-
regulated. A variety of calcium signaling pathway members
were dysregulated, the type 2 inhibitor of the calcium/
calmodulin dependent protein kinase II (Camk2n2) was
downregulated, while Camk2n1 and calcium/calmodulin
dependent kinase genes showed upregulations (Camk2g,
Camk2b). In accordance, the mRNA levels of Atp2b3,
Atp2b1 calcium transporting ATP-ases and Slc5a3, an in-
ositol transporter was also increased. Some of the voltage-
gated potassium transporter genes (Kcnd2, Kcnc2) were
upregulated (see Additional file 1: Table S1 for full results).
Gene set enrichment analysis
The GSEA analysis revealed altogether 18 differentially
represented gene sets in the HC region, including both
the Msig DB C5 gene set database and individually
chosen gene sets according to the literature (Additionalfile 2: Table S2), thus, protein kinase activity (GO:0004672),
protein kinase binding (GO:0019901), protein amino acid
phosphorylation (GO:0006468), symporter activity (GO:
0015293), phosphorylation (GO:0016310), secondary active
transmembrane transporter activity (GO:0015291), den-
drite development (GO:0016358), memory (GO:0007613),
regulation of synaptic plasticity (GO:0048167), cellular re-
sponse to retinoic acid (GO:0071300), positive regulation
of neuron projection development (GO:0010976), regula-
tion of synaptic transmission, glutamatergic (GO:0051966),
regulation of long-term neuronal synaptic plasticity
(GO:0048169), positive regulation of neuron differentiation
(GO:0045666), neuron projection terminus (GO:0044306),
regulation of excitatory postsynaptic membrane potential
(GO:0060079), cognition (GO:0050890) and synapto-
some (GO:0019717) gene sets were downregulated (see
Additional file 3: Table S3 for detailed results). We also
used in silico GSEA network analysis (Figure 2) on sig-
nificantly enriched gene ontology (GO) terms, which
represents functional connectivity and was applied to de-
termine biologically relevant processes shown in Table 1.
From the 18 differentially expressed gene sets ‘memory’
and ‘cognition’ and multiple pathways related to the
molecular function of kinases has to be emphasized
among processes related to synaptic plasticity and den-
drite and synapse development. The regulation of gluta-
matergic neurotransmission was also downregulated
(Table 1, in all cases, p < 0.05, and false discovery rate
(FDR) < 0.25). Figure 3 summarizes some of the main find-
ings of the GSEA analysis.
Frontal cortex
Differentially expressed genes
MDMA caused a significant underexpression of genes
related to the calcium signaling pathways (Camk2g and
Camk1g) and the ionotropic glutamate receptor, NMDA2B
(Grin2b). The alpha subunit of the heat shock protein 1
(Hspca) and the heat shock factor 2 (Hsf2) were up-
regulated, similarly to the high-affinity glial glutamate
transporter (Slc1a3) (see Additional file 1: Table S1 for
full results).
Gene set enrichment analysis
Altogether 55 gene sets were differentially enriched after
the single-dose MDMA treatment, containing both our
literature-based, individually chosen (Additional file 2:
Table S2) and Msig DB C5 gene sets. Additionally as
in the case of HC, we also used GSEA network ana-
lysis on significantly enriched GO terms (Figure 4) to de-
termine biologically relevant processes shown in Table 2.
The upregulated gene sets included the response to
hyperoxia (GO:0055093), positive regulation of synapse
assembly (GO:0051965), regulation of synaptic plasticity
(GO:0048167), growth factor activity (GO:0008083) and
Figure 2 Network analysis of the GSEA results in the Hippocampus. The network shows significantly (nominal p < 0.05, false discovery
rate < 0.25) enriched gene ontology (GO) terms in the gene set enrichment (GSEA) analysis in the hippocampus (HC) of Dark Agouti rats 3
weeks after a single-dose (15 mg/kg, intraperitoneal) 3,4-methylenedioxymethamphetamine (MDMA) administration. Blue circles represent the
downregulation of the associated terms, while red circles would represent upregulations. The size of the nodes is proportional with the number of
genes in the GO term and the thickness of the edges between lines represents the similarity coefficient. All processes in the HC are downregulated,
and two well characterized groups of processes emerge. On one hand the processes related to cognition and memory, e.g. regulation of synaptic
plasticity, dendrite development and regulation of glutamatergic synaptic transmission gene sets form diverse groups. On the other hand the
processes related to kinase activity form another network. See text for further details.
Table 1 Biologically relevant processes with enriched
gene sets in the hippocampal region
Biological process Number of enriched gene
sets related to the term
Direction
Protein phosphorilation 4 ⬇
Dendrite and synapse
development
4 ⬇
Synaptic plasticity 4 ⬇
Transmembrane transport 2 ⬇
Others 2 ⬇
Memory, cognition 2 ⬇
This table summarizes the biological processes significantly altered in the
hippocampus of Dark Agouti rats after a single-dose 3,4-methylenedioxy-
methamphetamine (MDMA) treatment (15 mg/kg, intraperitoneal) 3 weeks
earlier. The processes were created based on the network analysis of gene set
enrichment (GSEA) analysis and individual considerations. All significantly
enriched GO terms are included in one of the processes. Downward arrows
represent downregulations. See text for further details.
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http://www.biomedcentral.com/1471-2164/14/930dendrite development (GO:0016358) gene sets. While
organic acid transport (GO:0015849), carboxylic acid
transport (GO:0046942), translation (GO:0006412), macro-
molecule biosynthetic process (GO:0009059), pattern
specification process (GO:0007389), RNA binding (GO:
0003723), hydro lyase activity (GO:0016836), intracellular
protein transport (GO:0006886), establishment and or
maintenance of chromatin architecture (GO:0006325),
nuclear import (GO:0051170), protein import into nucleus
(GO:0006606), intracellular transport (GO:0046907), cellu-
lar biosynthetic process (GO:0044249), structural molecule
activity (GO:0005198), protein import (GO:0017038),
amine transport (GO:0015837), isomerase activity (GO:
0016853), amino acid transport (GO:0006865), biosynthetic
process (GO:0009058), structural constituent of ribosome
(GO:0003735), macromolecule localization (GO:0033036),
protein localization (GO:0008104), nuclear membrane part
(GO:0044453), protein transport (GO:0015031), nuclear
transport (GO:0051169), nucleocytoplasmic transport
(GO:0006913), establishment of protein localization
Figure 3 A schematic representation of MDMA’s sites of action in the Hippocampus. This figure summarizes the effects of a single-dose
(15 mg/kg, intraperitoneal) of 3,4-methylenedioxymethamphetamine (MDMA) 3 weeks earlier on hippocampal neurons in Dark Agouti rats. Three
distinct processes were identified marked by text boxes on the figure, phosphorylation- and dendrite development-related gene sets and gene
sets involved in the proper synaptic functioning were downregulated (signed with red crosses at possible sites of action). These processes can be
bound to memory and cognition gene sets (downregulated alike) through a single mediator, namely the type 1 cannabinoid receptor (CB1).
Accordingly, single-dose MDMA administration 3 weeks earlier resulted in elevated CB1 mRNA levels in the hippocampus. It has to be noted that
compared to the frontal cortical region (Figure 5), where rather intracellular signaling mechanisms were influenced, in the HC gene sets related
to the connectivity of neurons were damaged. See text for further details.
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acid transmembrane transporter activity (GO:0015171),
cell cycle arrest (GO:0007050), chromatin modification
(GO:0016568), hematopoietin interferon class d200
domain cytokine receptor activity (GO:0004896), electron
transport (GO:0006118), organic acid transmembrane
transporter activity (GO:0005342), endopeptidase activity
(GO:0004175), oxidoreductase activity (GO:0016491),
ribonucleoprotein complex (GO:0030529), cysteine type
peptidase activity (GO:0008234), negative regulation of
growth (GO:0045926), protein processing (GO:0016485),
carboxylic acid transmembrane transporter activity (GO:
0046943), chromosome organization and biogenesis
(GO:0051276), lipid transport (GO:0006869), cell cycle
process (GO:0022402), nuclear part (GO:0044428), mitotic
cell cycle (GO:0000278), protein-RNA complex assembly
(GO:0022618), RNA processing (GO:0006396), nuclear
envelope-endoplasmic reticulum network (GO:0042175),
establishment of cellular localization (GO:0051649) gene
sets were downregulated (see Additional file 3: Table S3
for detailed results). Classifying these gene sets into bio-
logical processes, the most prominent alterations were re-
lated to protein synthesis and protein localization within
the neurons and contained 21 significantly dysregulated
GO pathways, while 10 significantly enriched gene setswere involved in transport processes. All of these 31 gene
sets, without exception, were downregulated in the FC re-
gion, together with gene sets responsible for chromatin
maintenance. Among the upregulated gene sets in the
FC, dendrite and synapse development and growth
factor activity has to be emphasized 3 weeks after
MDMA administration (Table 2, in all cases, p < 0.05,
and FDR < 0.25). Figure 5 summarizes the main findings
of the GSEA analysis.
Dorsal raphe
Differentially expressed genes
In the DR region the glycine neurotransmitter trans-
porter (Slc6a5), the D-amino acid oxydase (Dao1) and
the 11-beta-hydroxisteroid dehydrogenase (Hsd11b1) genes
were downregulated among others (see Additional file 1:
Table S1 for full results).
Gene set enrichment analysis
In the DR region only one gene set, namely caspase acti-
vation was significantly downregulated after the single-
dose MDMA treatment. No upregulated gene sets could
be observed (in all cases p < 0.05, and FDR < 0.25). The
full results of the GSEA analysis in the DR region are
shown in Additional file 3: Table S3.
Figure 4 Network analysis of the GSEA results in the frontal cortex. The network shows significantly (nominal p < 0.05, false discovery
rate < 0.25) enriched gene ontology (GO) terms in the gene set enrichment (GSEA) analysis in the frontal cortex (FC) of Dark Agouti rats 3
weeks after a single-dose (15 mg/kg, intraperitoneal) 3,4-methylenedioxymethamphetamine (MDMA) administration. Blue and red circles represent
down- and upregulation of the associated GO terms, respectively. The size of the nodes is proportional with the number of genes in the GO term
and the thickness of the grey edges represents the number of common genes between two GO terms, if any. Most of the processes in the FC were
downregulated. The cellular biosynthetic process and establishment of cellular localization GO terms are in central positions of two different groups
while chromosome and chromatin organization, and transmembrane transport processes form the third and fourth group of tightly related,
downregulated gene sets. These alterations suggest a general neurotoxic effect while the upregulation of gene sets related to synapse formation
raises the possibility of a parallel running recovery process. The expression of the only immunologically related GO term was attenuated. See text
for further details.
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The heatmap (Figure 6) shows genes after two-way
hierarchical clustering comparing their expression
levels among all three regions. It provides a different
insight into the transcriptional changes after MDMA
treatment. In the HC region nearly all of the genes
were downregulated. In contrast, most of those genes
that were downregulated in the FC were found to be
upregulated in the HC, suggesting marked differences
between the two regions. Changes in the DR werescant independently of alterations in the other two
regions.
Discussion
In this study we evaluated the transcriptional conse-
quences three weeks after a single neurotoxic dose of
MDMA in DA rats with gene expression arrays. MDMA’s
effects on the transcriptional level suggest alterations in
cognition and memory related processes with the pos-
sible involvement of the CB1 and ephrin receptors in the
Table 2 Biologically relevant processes with enriched
gene sets in the frontal cortical region
Biological process Number of enriched gene
sets related to the process
Direction
Protein synthesis and
localization
21 ⬇
Transmembrane transport 10 ⬇
Nucleocytoplasmic transport 7 ⬇
Cell growth 6 ⬆⬇
Others 4 ⬆⬇
Chromatine maintenance 3 ⬇
Dendrite and synapse
development
3 ⬆
Oxidoreductase acitivity 2 ⬇
This table summarizes the biological processes significantly altered in the
frontal cortex (FC) of Dark Agouti (DA) rats after a single-dose 3,4-methyle-
nedioxymethamphetamine (MDMA) treatment (15 mg/kg, intraperitoneal) 3
weeks earlier. The processes were created based on the network analysis
of gene set enrichment (GSEA) analysis and individual considerations. All
significantly enriched GO terms are included in one of the processes.
Downward arrows represent down-, upward arrows represent upregulations.
In some of the biological processes both up- and downregulated gene
sets were present (mixed up- and downward arrows). See text for
further details.
Figure 5 A schematic representation of MDMA’s sites of action in the
(15 mg/kg, intraperitoneal) 3,4-methylenedioxymethamphetamine (MDMA)
Dark Agouti rats. The text boxes mark the selected, grouped processes whi
genes involved in different levels of protein synthesis were downregulated
folding and localization and members in the transport of amino acids and
wide-scale impairment of the cellular machinery. However, the formation of n
on a different scale. See text for further details.
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scale changes in basic catabolic processes within FC
cells and the upregulation of the ‘dendrite development’,
‘regulation of synaptic plasticity’ and ‘positive regula-
tion of synapse assembly’ gene sets suggest a partial
new synapse formation/synaptic reorganization in this re-
gion. These differences between the HC and FC indicate
markedly different transcriptional responses of these two
brain regions three weeks after a single dose MDMA
administration.
Hippocampus
In the HC we observed an upregulation of CB1 receptor
mRNA. Nawata et al. also investigated CB1 receptor mRNA
levels in the HC regions of mice up to 7 days following the
cessation from repeated MDMA administration and they
reported an increase 7 days, but not 1 day after the last
treatment [43]. Our study shows that an increase of CB1
receptor levels can be caused even by a single-dose of
MDMA and can be detected three weeks after the drug ad-
ministration in rats. The presence of elevated CB1 receptor
mRNA levels in both rats and mice, which have markedly
different reactions to MDMA on the long-run [44], raises
the possibility of such effects in human ecstasy users alike.
Selective serotonin reuptake inhibitor (SSRI) treatment
is known to cause alterations in CB1 receptor levels infrontal cortex. This figure summarizes the effects of a single-dose
administration 3 weeks earlier on the frontal cortex (FC) neurons of
le red crosses represent the possible sites of action. Almost all of the
, including nucleocytoplasmic transport, ribosome functioning, protein
lipids, basic constituents of the cells. These changes strongly suggest a
ew neuronal connections can compensate for these effects (not depicted)
Figure 6 Correlation between the microarray and the Fluidigm
GEx PCR array data. The figure summarizes the correlation
between the logarithmic microarray data and the validation results
for both the 200 ng and 500 ng samples. For validation purposes
we used the polymerase chain reaction-based (PCR-based) Fluidigm
GEx array with 19 genes and upon receiving the results, the numerical
analysis was performed with the inbuilt corr.test function of the
R statistical computing program. The results are in agreement with the
commonly observed decreasing accuracy of the fold change values of
the microarray method at the higher and lower ends. The correlation
coefficients were 0.619 and 0.610 for the 200 ng and 500 ng samples,
respectively. Red line represents the regression line.
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quences of the altered serotonergic tone. Activation of
serotonin 2C (5-HT 2C) receptors increases endocanna-
binoid production in the postsynaptic HC and amygdala
neurons via the downstream activation of diacylglycerol
(DAG) lipase [45]. The released 2-arachidonoil glycerol
(2-AG) acts on the presynaptic neurons, and inhibits
serotonin (5-HT) release through CB1 receptor activa-
tion thus forming a negative feedback loop [45]. MDMA
treatment leads to a long-term serotonergic deficiency
and to the damage of serotonergic axon terminals
[2,5-7]. Hence, the result of the decreased endocannabi-
noid release from postsynaptic neurons might result in the
observed upregulation of the CB1 receptor.
Cannabinoid agonists impair working memory and
short term memory [36,39-41] and it has been also
reported that MDMA can cause impairments in cogni-
tive functions in humans, rats and mice [2,6,8-10,43].
Nawata et al. also showed that CB1 receptor antagonist
attenuated the MDMA-induced cognitive deficit in mice
[43]. Accordingly, we observed in the present study that
genes involved in the regulation of memory and cogni-
tive processes were downregulated after MDMA treat-
ment in DA rats. The latter findings and the fact that
both CB1 receptor elevations and cognitive deficits
are present in multiple species suggest a central role
of CB1 receptor and thus cannabinoid signaling in the re-
duced cognitive and memory functions following MDMA
administration.
CB1 receptors exert their effects in the cells via
calcium-signaling, thus upregulation of some of the cal-
cium/calmodulin-dependent kinases (CAMK), calcium
transporters, an inositol transporter and the phosphoryl-
ation gene set may be in association with CB1 receptor
signaling. In addition, enhancement in cannabinoid sig-
naling usually indirectly reduces glutamate release by
acting on GABA-ergic interneurons in the HC (for a re-
view see [47]). Accordingly, genes belonging to the regu-
lation of the glutamatergic synaptic transmission were
downregulated in the present study. Finally, elevated
CB1 receptor signaling has been shown to impair neurite
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cannabinoid agents in adult mice were able to modulate
synaptic plasticity [48-50]. In accordance, we also ob-
served downregulations in ‘neuron projection develop-
ment’ and synaptic plasticity related gene sets.
Here we also show upregulations of the mRNA levels
of Epha4, Epha5 and Epha6 receptors in the HC after
MDMA administration. These receptors have been re-
ported to modulate synapse formation and glutamatergic
long-term potentiation (LTP) (for a review see [51]).
Since ephrin receptors are bidirectional receptors and
regulate both presynaptic and postsynaptic neurons, the
up- or downregulation of these receptors does not result
in consequent elevation or suppression of synapse for-
mation. Instead, a proper level of these receptors is re-
quired for accurate neuronal projection termination
[52]. While Epha4 and Epha6 are widely expressed in
the HC, Epha5 is weakly labeled in this region under
physiological conditions [53-55]. Epha4 was found to
suppress synapse development in the HC [56], while
Epha5 knock-out (KO) mice showed decreased spine
density in other brain regions [42] and may be necessary
for proper hippocampal projections [57,58]. In another
study, Epha6 KO mice showed impaired cognitive func-
tions [59]. Thus, it is clear that ephrin receptors modu-
late synapse formation in the HC and related cognitive
functions.
Frontal cortex
While alterations in the expression of 5-HT markers are
well-defined, studies examining other effects of MDMA
on gene expression are scarce. Thiriet et al. examined
1176, toxicology-related genes in adult Sprague–Dawley
rats and followed expression patterns up to 7 days after
a 20 mg/kg single-dose MDMA administration in the
FC [60]. They found nerve growth factor alterations and
suggested cytoskeletal reorganization while in another
study by Fernandez-Castillo et al. emphasized neuroin-
flammatory responses in MDMA-effects 8 hours after
repeated-administration in adult mice [61]. Martinez-
Turillas et al. investigated brain-derived neurotrophic
factor augmentations in the FC region of Wistar rats up
to 7 days after drug administration [34]. In our present
study we examined the gene expression patterns longer
time (3 weeks) after a single neurotoxic dose of MDMA
in the vulnerable DA rat strain. We report wide-scale
downregulation of genes involved in chromatin orga-
nization, nucleocytoplasmic transport, ribosome-related
functions, protein synthesis/folding and transmembrane
transport processes in the FC region (Figure 5). It seems
reasonable that the observed changes are the long-term
consequence of the acute general neurotoxic pro-
cesses, like toxic metabolite formation, hyperthermic
effect or free radical production or the impairment in theautoregulation of cerebral blood flow [5,11-19]. The latter
is even further supported by the upregulation of the re-
sponse to hyperoxia gene set in the present study. We
could not confirm neuroinflammatory changes [61] or
BDNF dysregulation [34] observed by other authors in our
experimental setup. In comparison with the previous study
of Thiriet et al. [60], the growth factor activity gene set was
upregulated, while some gene sets, related to neuronal
cytoskeletal transport were downregulated in line with the
previous study. However, this similarity existed only on the
level of the mentioned biological processes, and was a re-
sult of the dysregulation of other genes, a possible result of
the differences in the strain, time-scale and dosage regimen
between the two studies.
Motor regions in the FC are targets of thalamical in-
puts and contribute to motor system functions [62].
Studies in DA rats with the same MDMA administra-
tion protocol like in the recent experiment indicated
chronic changes in motor activity [63-65]. Additionally,
Karageorgiou et al. reported alterations in right supple-
mentary motor area activation in human MDMA users
in an fMRI study [66]. These results might reflect subse-
quent impairments in motor functions on the long-run
and are in accordance with the observed wide-scale
changes in the recent experiment.
As from another functional perspective FC and pre-
frontal cortical regions (PFC) are not only responsible
for motor functions, but are also closely related to differ-
ent cognitive tasks, e.g. working memory, goal-directed
behavior, and executive functioning in rats [26,67-69]. In
our experiment FC samples contained regions from pri-
mary and secondary (supportive) motor cortices princi-
pally and likely some parts of the PFC [69]. Thus the
inhibition of certain biosynthetic processes found in the
present study may even participate in the cognitive
decline of heavy MDMA users.
At the same time, however, upregulation of neurite
formation related gene sets and thus a partial reinstate-
ment of FC networks is also suggested by our present
data. Additionally, the upregulation of HSP-related genes
in the present study also suggests different extent in re-
covery processes. The latter results and the lack of simi-
lar processes in the HC might point out to different
severity of damage of different memory types. Indeed,
the only study investigating such differences following
binge administration of MDMA, reported rats learning
working-memory related tasks (mainly FC mediated) fas-
ter on the long-run compared to spatial reference mem-
ory (mainly HC mediated) in an 8-arm radial maze
challenge [70].
Taken together, the downregulation of almost 50 gene
sets related to biosynthetic processes in the FC may re-
flect transcriptional adaptations to well-known general
neurotoxic effects not related to specific pathways 3
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the upregulation of the gene sets responsible for synapse/
dendrite formation in this brain region may point to a
starting new synapse formation/synaptic reorganization
and might be a sign of a compensatory mechanism
ameliorating MDMA’s acute effects 3 weeks after the
administration.
Dorsal raphe
The changes in the DR region were mild in line with our
previous results suggesting that MDMA-caused damage
to these neurons are restricted to serotonergic axon ter-
minals instead of neuronal cell bodies directly [71]. The
caspase activation gene set significantly changed in the
present study was not supported by individual genes, or
other gene sets related to apoptotical processes. The
downregulation in 11beta-hydroxysteroid dehydrogenase
type 1 mRNA levels might suggest a possible role of the
hypothalamic-pituitary-adrenal axis in MDMA’s long-
term consequences, an effect also proposed by others
[72,73]. However, the DR region seems to be mostly un-
affected 3 weeks after a single-dose of MDMA adminis-
tration in DA rats.
Limitations
In the present study we have not elucidated the tem-
poral patterns of the mRNAs. Further studies are needed
addressing the time course of the described alterations
to elicit the causative relations of these transcriptional
processes in details.
We could not confirm the decreased expression of se-
rotonergic markers in the present study. Both 5-HTT
and TPH mRNA levels were unaltered in the treatment
group, which is in conflict with previous results: well
established prolonged serotonergic depletion and de-
creased expression of serotonergic markers in both protein
and mRNA levels after MDMA-treatment were demon-
strated by our group earlier [5,6]. Here we can assume that
the collection of DR samples was not precise enough and
as we did not apply laser capture microdissection in this
case, significant amount of surrounding tissue was perhaps
cut out together with the DR and it may result a bias in
the measurement of serotonergic markers. Notably, the
decrease of 5-HTT expression, measured by quantitative in
situ hybridization, was approximately −20% in the same
animal model 3 weeks after the MDMA treatment, com-
pared to the control level, and this moderate alteration was
significant only in case of the fine measurement of grain
densities of individual cells but not with the measuring of
the autoradiography signal on film [6].
On the other hand, microarray method has well-known
drawbacks, when compared to polymerase chain reaction
methods or immunohistochemistry used in our earlier
papers. Namely, the limited amount of probes on themicroarray may result in smaller fold change values, when
compared to polymerase chain reaction methods (PCR),
which can also be noticed on Figure 7. On the other hand,
the shorter oligomers used can result in more mismatch
hybridization, which can overcome smaller changes in gene
expressions, like that in the case of 5-HTT. However, for
this very reason we assume that the results presented here,
with our strict significance criterion, are robust enough to
overcome this bias.
We did not find alterations in the BDNF gene expres-
sion, which is in agreement with our previous study where
we demonstrated that (after a slight transient acute de-
crease) BDNF protein level was increased only 8 weeks
after the same MDMA dosage regimen in the same rat
strain [35].
We must also note the major limitation of transcrip-
tomic studies, namely, mRNA levels do not necessarily
reflect for the appropriate protein levels.
Conclusion
We performed a genome-wide evaluation of transcrip-
tional changes 3 weeks after a single-dose of MDMA in
DA rats. Our results highlight CB1 and ephrin receptors
as potential downstream mediators of MDMA in the
HC. In addition, GSEA showed downregulation of the
‘cognition’ and ‘memory’ gene sets and also indicated a
decreased functionality of long-term potentiation and
the possible involvement of the hippocampal glutamater-
gic pathway in these processes. However, determination
of causative relations or possible interactions between
the observed changes requires further investigations.
On the other hand, the FC region showed markedly
different changes. The differences compared to the HC
were obvious by both the GSEA and by the heatmap
analysis. These differences may reflect for the different
anatomical properties/connectivity and also the different
neurotransmitter contents of these regions. The down-
regulated pathways in the FC were related to the basic
mechanisms of the cell functionality in the absence of
specific markers of certain pathways. In the FC the up-
regulation of the ‘dendrite development’, ‘regulation of
synaptic plasticity’ and ‘positive regulation of synapse
assembly’ gene sets raise the possibility of new synapse
formation/synaptic reorganization mechanisms in this
region. In contrast, these gene sets were not upregulated
in the HC. All of these results point out to a starting re-
instatement of the neuronal pathways and connections
in the FC, but not in the HC, three weeks after a 15 mg/kg
dose of MDMA.
Methods
Animals
The animal experiments and housing conditions were
carried out in accordance with the European Community
Figure 7 Correlation between the microarray and the Fluidigm GEx PCR array data. The figure summarizes the correlation between the
logarithmic microarray data and the validation results for both the 200 ng and 500 ng samples. For validation purposes we used the polymerase
chain reaction-based (PCR-based) Fluidigm GEx array with 19 genes and upon receiving the results, the numerical analysis was performed with
the inbuilt corr.test function of the R statistical computing program. The results are in agreement with the commonly observed decreasing accuracy of
the fold change values of the microarray method at the higher and lower ends. The correlation coefficients were 0.619 and 0.610 for the 200 ng and
500 ng samples, respectively. Red line represents the regression line.
Petschner et al. BMC Genomics 2013, 14:930 Page 11 of 15
http://www.biomedcentral.com/1471-2164/14/930Council Directive of 24 November 1986 (86/609/EEC), as
well as the National Institutes of Health Principles of
Laboratory Animal Care (NIH Publication 85–23, re-
vised 1985) and special national laws (the Hungarian
Governmental Regulation on animal studies, 31 December
1998 Act). The experiments were approved by the National
Scientific Ethical Committee on Animal Experimentation
and permitted by the Food Chain Safety and Animal
Health Directorate of the Central Agricultural Office,
Hungary (permission number: 22.1/3152/001/2007).
Altogether 21 male DA rats (Harlan, Olac Ltd, Shaw’s
Farm, Blackthorn, Bicester, Oxon, UK) aged approxi-
mately 8 weeks (weighing 152 ± 3,58 g (SEM) at the be-
ginning of the experiment) were used. The animals (four
per cage) were kept under controlled environmental
conditions along the whole experiment (temperature
21 ± 1°C, humidity: 40-50%, 12 hour light–dark cycle
starting at 6:00 a.m.) and food and water were avail-
able for them ad libitum.
Drug administration and experimental design
(±)3,4-methylenedioxymethamphetamine (Sanofi-Synthelabo-
Chinoin, Hungary, purity >99.5%) was dissolved in 0.9%
NaCl (SAL) at an equivalent dose of 15 mg/kg free baseand was administered intraperitoneally (i.p.) in a volume of
1 ml/kg. For control animals SAL was used i.p. in equiva-
lent volumes (1 ml/kg).
The MDMA-treated and control groups consisted of
11 and 10 animals, respectively, and were randomly
assigned to each group. Vehicle-containing Alzet 2001
osmotic minipumps (Durect Corp., CA, USA) were
inserted under the skin for all animals. The rats were sacri-
ficed 3 weeks after the injections.
RNA extraction and sample preparation
Three weeks after MDMA or vehicle injections rats
were killed quickly by decapitation. The brains were
removed, approximately 2 mm thick coronal sections
were cut and the HC, FC and DR regions were dis-
sected according to Paxinos and Watson ([74], dorsal
HC: from bregma −2.5 mm to −4.5 mm; FC: from
bregma +1.7 to −0.3 mm; DR: from bregma −7 mm
to −8 mm, respectively) and stored at −80°C. The samples
were homogenized with 1 ml TRIzol reagent (Ambion,
TX, USA) according to the manufacturer’s instructions.
Thus, the homogenized samples were centrifuged at
12000 g at 4°C for 10 minutes, the supernatant transferred
to a new sterile Eppendorf tube and incubated at room
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200 μl was added; the mixture was vortexed and incubated
again at room temperature for 2–3 minutes. Following
centrifugation at 12000 x g at 4°C for 15 minutes the
upper (clear) aqueous phase was transferred to a new
Eppendorf tube and was mixed with 500 μl of isopropra-
nol and incubated for 10 minutes at room temperature.
After centrifuging the samples at 12000 x g at 4°C for 10
minutes the supernatant was removed and 1 ml 75% etha-
nol was added to the precipitation. The samples were
again centrifuged at 7500 x g at 4°C for 5 minutes, the
supernatant was removed, and 1 ml 75% ethanol was
added. After centrifuging samples at 7500 x g at 4°C for 5
minutes, the ethanol was removed, and the RNA pellets
briefly dried. The pellets were dissolved in 20 μl diethyl-
pyrocarbonate treated-dH2O (DEPC-dH2O) and the sam-
ples stored at −80°C until further processing.
To determine the quality of the samples 1–2 μl were
used for optical density (OD, 260/230 and 260/280
ratios) measurements. The OD ratios were determined
for all samples and randomly repeated to evaluate the
reliability of the measurements (no significant difference
was observed, data not shown). Samples with the lowest
RNA concentrations were excluded from further analysis
and thus both MDMA and control groups consisted of
8 animals. Two-two randomly selected samples were
pooled in each treatment group resulting in 4 pooled sam-
ples per brain region and per treatment group. These sam-
ples (altogether 24 samples) were sent to Service XS
(Leiden, Netherlands) for microarray analysis with the
Illumina (San Diego, CA, USA) RatRef-12 v1 beadarray
expression chip. Upon arrival, samples were once again
subjects to a purification process and quality control
measurements with Agilent Bioanalyzer and Nanodrop
spectrophotometer and one sample from the DR region
was excluded from further analysis due to degradation.
Data analysis
Raw microarray data were processed with beadarray
[75], preprocessCore [76] and puma [77] Bioconductor
[78] packages for R [79] as described in [80]. Briefly,
backgroundCorrect method used in the beadarray pack-
age was set to “minimum”, and “log = TRUE; n = 10” var-
iables were used for createbeadsummaryData method.
The normalization method used was the quantile nor-
malization method in the preprocessCore package. Add-
itionally, pumaComb, pumaDE, and write.rslts functions
with default settings were used. Changes were consid-
ered statistically significant when the MinPplr was below
0.001. This strict criterion was necessary to reduce the
number of false positive results to an acceptable limit.
Heatmap visualization of the differences in gene ex-
pression was done using Multiexperiment Viewer Tool
[81,82]. Genes with similar expression patterns are groupedtogether with hierarchical clustering (Euclidean distance,
average linkage) [83].
GSEA was performed using GSEA version 3.1 from
the Broad Institute at MIT (http://www.broadinstitute.
org/gsea) [84,85]. Gene sets (GMT format) were ob-
tained from the MSigDB for C5 category (GO gene sets)
and in addition, neuronal function related gene sets were
selected from the GO homepage (www.geneontology.
org; [86]) manually. Gene identifiers used in the array
dataset and gene sets were gene symbols. The data set
had 22523 features (Illumina probes), which were collapsed
to gene symbols (the median expression value was used for
the probe set). In these analyses, the gene sets analyzed
were restricted to those sets containing between 15 and
500 genes as recommended [87]. The t-test was used as
the metrics for ranking genes and gene set was chosen as
the permutation type since the sample size was less than 7
in this study. 1000 permutations were used to calculate
p-value with the seed of permutation set to 149. All
other basic and advanced fields were set to default.
A normalized enrichment score (NES) was calculated
for each gene set to represent the degree in which it was
enriched in one phenotype. The nominal p-value and
the FDR corresponding to each NES were calculated. A
NES with a nominal p-value <0.05, FDR <0.25 were con-
sidered statistically significant.
Network visualization and analysis using enrichment
results was done using Cytoscape 2.8.3. and its plugin
“Enrichment Analyzer” with the following cut-offs: simi-
larity coefficient cut-off 0.1, p-value cut-off 0.05 and
FDR cut-off 0.25 [88,89].
PCR validation
We have validated altogether 19 RNA products from the
original pooled samples with real-time PCR on Fluidigm
GEx array (San Francisco, CA, USA) using Taqman Gene
Expression assays for the appropriate RNAs obtained from
Applied Biosystems (Carlsbad, CA, USA) (for the full list
of validated genes see Additional file 4: Table S4). Each
sample was used in duplo following quality control mea-
surements (altogether three samples were excluded due to
degraded or insufficient amount of RNA). The validation
experiment was performed by Service XS (Leiden,
Netherlands). Upon arrival of the normalized results,
manually written R scripts using the cor.test function with
default settings were used for the comparison between
microarray and PCR data. The Pearson correlation coeffi-
cients were 0.619 and 0.610 for the 200 ng and 500 ng
samples, respectively. In both cases p-values were far below
0.001. The linear regression is depicted on Figure 7.
Availability of supporting data
The data supporting the results of this publication have
been deposited in NCBI’s Gene Expression Omnibus
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query/acc.cgi?acc=GSE47541).
Additional files
Additional file 1: Table S1. Contains significantly up- or downregulated
genes compared to the control group in the three examined brain region.
Additional file 2: Table S2. Contains individually selected GO terms for
GSEA analysis.
Additional file 3: Table S3. Contains the significantly enriched GO
terms selected by NES, FDR and nominal p-values (nomP) in the exam-
ined brain regions.
Additional file 4: Table S4. Contains the genes validated with the
Fluidigm GEx PCR array and the used TaqMan assays.
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